Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...

UK: A recent retrospective cohort study has highlighted the critical role of kidney function in patients diagnosed with ...

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...

BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...

The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

See the new treatment that will break a Pfizer monopoly on a drug for heart disease.

Eplontersen is recommended, within its marketing authorisation, as an option for treating hereditary transthyretin-related amyloidosis in adults with stage 1 or stage 2 polyneuropathy. It is only ...

Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...

Eplontersen (Wainzua, AstraZeneca) is indicated for 'treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with stage 1 and 2 polyneuropathy'. The list price ...

The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...